Hydroxyamine

Hydroxyamine

SCHEMBL7685608

C=CCC(C=CC)(C(=O)O)S(=O)(=O)c1ccc(OC)cc1.NO

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 8/20 0.55
MMP13 P45452 8/20 0.55
MMP1 P03956 7/20 0.55
ADAM17 P78536 2/20 0.43
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
F2 P00734 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
KEAP1 Q14145 2/20 0.37
NFE2L2 Q16236 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
FFAR4 Q5NUL3 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7622218 0.97 MMP13 (0.57) MMP9MMP13MMP1ADAM17HTT
SCHEMBL7514126 0.83 MMP13 (0.53) MMP9MMP13MMP1ADAM17HTT
Hydroxyamine SCHEMBL7951948 0.82 MMP9 (0.70) MMP9MMP13MMP1ADAM17HTT
SCHEMBL6930481 0.79 MMP13 (0.74) MMP9MMP13MMP1ADAM17HTT
Hydroxyamine SCHEMBL8229937 0.74 MMP13 (0.60) MMP9MMP13MMP1ADAM17HTT
SCHEMBL7626034 0.74 MMP9 (0.55) MMP9MMP13MMP1ADAM17HTT
SCHEMBL8223970 0.71 MMP13 (0.62) MMP9MMP13MMP1ADAM17HTT
SCHEMBL6928954 0.71 MMP13 (1.00) MMP9MMP13MMP1ADAM17
SCHEMBL1464319 0.71 PKM (0.52) MMP9MMP13MMP1ADAM17HTT
Hydroxyamine SCHEMBL7571652 0.70 MMP13 (0.72) MMP9MMP13MMP1ADAM17HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6441023-B1 FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION AMERICAN HOME PRODUCTS CORPORATION 2002-08-27 US disclosed
US-20020032186-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors AMERICAN CYANAMID COMPANY (US) 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032186-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors MMP12, ADAM33, MMP2 MMP9 13/4885MMP13 27/4885MMP1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.